Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel

por Langer, C J, Hirsh, V, Okamoto, I, Lin, F-J, Wan, Y, Whiting, S, Ong, T J, Renschler, M F, Botteman, M F
Publicado 2015

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (...

por Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C.
Publicado 2010

The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national conse...

por Ellis, P.M., Morzycki, W., Melosky, B., Butts, C., Hirsh, V., Krasnoshtein, F., Murray, N., Shepherd, F.A., Soulieres, D., Tsao, M.S., Goss, G.
Publicado 2009

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

por Paz-Ares, L., Tan, E.-H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.-H., Mok, T., Lee, K. H., Lu, S., Shi, Y., Lee, D. H., Laskin, J., Kim, D.-W., Laurie, S. A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K.
Publicado 2017